BIOTECH MARKET RESEARCH $RLAY | Ep. 948
Relay Therapeutics
Relay Therapeutics ($RLAY) has become a catalyst-driven trade into its ASCO June 2026 update on zovegalisib (RLY-2608) in 2L HR+/HER2- PIK3CA-mut metastatic breast cancer, with investors framing the presentation as a referendum on whether the 400 mg BID fed pivotal dose can reproduce the earlier 10.3-month mPFS signal seen at 600 mg fasted. The stock only re-rates if ASCO demonstrates durable PFS in the ≥9–10 month range with ORR holding in the mid-to-high 30s, reinforcing the mutant-selective PI3Kα differentiation thesis versus capivasertib and legacy PI3K inhibitors. Investors will overweight absolute median PFS, separation from the historical 5–7 month CDK4/6-experienced benchmark, consistency across kinase and non-kinase PIK3CA subsets, and whether safety remains clearly cleaner on hyperglycemia and discontinuations at the fed dose used in Phase 3. If the ASCO dataset shows efficacy compression toward 7–8 months, right-tail erosion, or emerging metabolic toxicity that converges toward non-selective pathway inhibitors, the narrative shifts to “Phase 2 inflation risk,” pressuring confidence in ReDiscover-2 and pushing RLAY back toward a binary, Phase 3-dependent story rather than a de-risked best-in-class setup. Options are pricing +/- 135% volatility.
Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.
We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).
Be sure to SUBSCRIBE to not miss.
HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS
While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.
This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.
🚨 ALERT: ASCO data readout June 2026
📅 TIMING: June 2026
📈 IMPLIED MOVE: ~±135%
BACKGROUND:
About the company:
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com
PORTFOLIO:
The company’s can be seen below:
What Biotech Investors Need to Know
Anchor expectations to absolute mPFS magnitude at 400 mg BID fed and durability of separation versus historical 2L benchmarks, not cross-trial enthusiasm around the earlier 10.3-month Phase 2 signal. The catalyst is ASCO June 2026, and the key question is whether the pivotal fed dose reproduces the efficacy seen at 600 mg fasted while maintaining a clearly differentiated safety profile against capivasertib and legacy PI3Kα inhibitors.
Bulls want mPFS holding in the ≥9–10 month range, ORR sustained in the mid-to-high 30s, and clean Kaplan-Meier curves without early drop-off or right-tail collapse. They will focus on consistency across kinase and non-kinase PIK3CA mutations, durability beyond 9 months, and hyperglycemia/discontinuation rates that remain meaningfully below non-selective pathway inhibitors. A clean dataset de-risks ReDiscover-2 and reinforces the “best-in-class mutant-selective PI3Kα” narrative heading into Phase 3.
Bears will look for classic Phase 2-to-Phase 3 inflation risk: mPFS compression toward 7–8 months, early curve convergence, loss of kinase subset outperformance, or creeping metabolic toxicity at the fed dose. If efficacy drifts toward the historical 5–7 month CDK4/6-experienced range or safety converges with existing PI3K/AKT agents, the narrative shifts to “incremental, not differentiated,” and the stock likely reverts to a binary Phase 3-dependent valuation with limited premium for best-in-class positioning.
Confidence in mechanism
Confidence in mechanism should be discounted, not assumed, until ASCO June 2026 demonstrates that the 400 mg BID fed pivotal dose reproduces the durability signal seen at 600 mg fasted without efficacy compression or safety convergence. Mutant-selective PI3Kα inhibition is biologically coherent, but coherence is not confirmation. The mechanism must prove it can meaningfully extend PFS beyond the historical 5–7 month ceiling observed across CDK4/6-experienced HR+/HER2- disease.
Pathway redundancy is a structural risk. PI3K signaling sits upstream of AKT and mTOR and interacts with MAPK and RTK escape routes. Excluding PTEN and AKT co-alterations in Phase 2 enriched for cleaner biology, but real-world tumors are heterogeneous. If benefit narrows outside idealized molecular subsets, the mechanism is more conditional than broad.
Selectivity may trade potency for tolerability. The thesis is that mutant selectivity reduces wild-type PI3Kα inhibition and metabolic toxicity. But less wild-type inhibition may also mean less total pathway suppression in tumors with clonal heterogeneity. If depth of response depends on broader pathway tone suppression, excessive selectivity risks limiting durability.
PFS does not equal structural resistance control. A median PFS advantage can reflect early cytostasis rather than durable clonal suppression. If Kaplan-Meier curves separate early but converge by 9–12 months, the mechanism reads as transient pathway damping rather than sustained biology modification.
Subset dependency would weaken the thesis. Phase 2 data suggested stronger outcomes in kinase-domain mutations. If ASCO shows benefit concentrated in kinase mutations with flattened curves in non-kinase tumors, the narrative shifts from broad PIK3CA control to niche mutation targeting, materially compressing peak assumptions.
Dose bridging introduces uncertainty. The efficacy anchor was generated at 600 mg BID fasted, while Phase 3 and the ASCO validation rely on 400 mg BID fed. Pharmacokinetic comparability does not guarantee equivalent intratumoral pathway suppression. If efficacy drifts at the fed dose, the mechanism proves dose-fragile.
Safety at scale remains unproven. Hyperglycemia rates were manageable in a metabolically selected population with HbA1c <7%. In broader use, even partial wild-type PI3K inhibition may accumulate metabolic liabilities. If dose reductions or discontinuations rise with longer exposure, the effective pathway inhibition ceiling compresses.
Cross-trial benchmarking inflates confidence. Historical comparisons to capivasertib or alpelisib are directionally useful but mechanistically noisy. Confidence only upgrades when superiority is demonstrated against contemporary standard of care in a large randomized setting, not when small Phase 2 cohorts outperform across-study medians.
Regulatory framing can redefine the mechanism. Even with statistical PFS improvement, narrow subgroup benefit, immature OS, or safety caveats can reclassify the drug as incrementally improved rather than best-in-class. Label breadth ultimately determines whether the mechanism is viewed as transformative or iterative.
What upgrades confidence: clear and durable PFS separation at 400 mg fed with median ≥9–10 months, stable hazard ratios over time without curve convergence, consistent benefit across kinase and non-kinase PIK3CA mutations, maintained full-dose combinability without exposure erosion, and early regulatory alignment that the effect reflects durable resistance suppression rather than transient pathway inhibition.
PK, exposure, and distribution
PK is central to whether zovegalisib’s mutant-selective PI3Kα differentiation actually translates clinically, and here the data are directionally supportive but not fully de-risked. The claim is not merely selective binding, but sustained pathway suppression at exposures sufficient to control both kinase and non-kinase PIK3CA mutations without triggering wild-type metabolic toxicity that forces dose compromise. That requires durable target coverage, not just overlapping steady-state curves.
Steady-state pharmacokinetic measures show that 400 mg BID fed achieves exposure comparable to 600 mg BID fasted, with similar trough concentrations and AUC at Cycle 1 Day 15. FDA alignment on 400 mg fed as the pivotal dose reduces dose-bridging uncertainty and supports the argument that Phase 3 exposure should approximate the earlier efficacy dataset. Directionally, this meaningfully de-risks one common development failure mode.
PK equivalence does not guarantee identical pharmacodynamics. Plasma exposure curves do not confirm intratumoral PI3K pathway suppression over time, particularly in heterogeneous metastatic disease with variable clonal architecture. If ASCO data show efficacy compression at 400 mg fed, exposure similarity alone cannot clarify whether the issue is insufficient pathway depth, altered tissue penetration, or biological redundancy downstream.
Exposure–response linkage remains limited publicly. While steady-state exposure appears adequate, detailed exposure–response modeling correlating plasma levels with PFS durability across kinase and non-kinase subsets has not been extensively disclosed. Without that linkage, it is unclear whether zovegalisib operates with a wide therapeutic window or whether benefit sits near a narrower exposure threshold vulnerable to real-world variability.
Combination exposure complicates attribution. In Phase 3, zovegalisib is paired with fulvestrant. If tolerability signals increase over longer follow-up and dose intensity drifts, effective pathway suppression may erode despite nominal PK adequacy. Early combination data appear manageable, but larger randomized exposure is the true stress test.
Metabolic tolerability intersects directly with exposure durability. Even partial wild-type PI3Kα inhibition can drive hyperglycemia and insulin resistance. If metabolic effects accumulate at scale, maintaining consistent exposure may become harder than early, metabolically selected cohorts suggest. PK robustness only matters if patients can remain at target dose.
What upgrades confidence: ASCO confirmation that 400 mg BID fed delivers durable ≥9–10 month mPFS consistent with the 600 mg fasted dataset, absence of dose-intensity erosion over time, stable hyperglycemia rates supporting chronic exposure, and emerging exposure–response analyses demonstrating consistent benefit across mutation subtypes. Today, PK data meaningfully reduce dose-bridging concern, but do not fully eliminate mechanistic uncertainty until pivotal-dose clinical durability is demonstrated.
PD read-through
PD read-through into the ASCO June 2026 catalyst is a pathway-suppression and durability test, not a question of whether PI3K signaling can be inhibited acutely. The update will determine whether mutant-selective PI3Kα inhibition meaningfully suppresses downstream signaling in CDK4/6-experienced disease or whether PD effects plateau once layered onto endocrine therapy.
Acute pathway inhibition is not the debate. ctDNA reductions and early tumor shrinkage demonstrate biological activity, and prior PI3K pathway datasets confirm measurable target engagement. The open question is whether incremental PD suppression in a resistance-evolved setting translates into durable PFS extension beyond the historical 5–7 month range already achieved with downstream AKT inhibition.
PD durability is the unresolved risk. High rates of early PIK3CA ctDNA decline and clearance were observed at 600 mg BID fasted . That is directionally supportive of target engagement. But early ctDNA clearance does not guarantee sustained pathway suppression. If Kaplan-Meier curves at ASCO separate early and converge later, it implies downstream reactivation or adaptive bypass despite initial PD depth.
Mutation-subtype behavior is the key PD stress test. If kinase-domain mutations show sustained separation while non-kinase tumors flatten, the PD effect may be mutation-context dependent rather than broadly transformative. Durable downstream control across both kinase and non-kinase subsets would meaningfully strengthen mechanistic confidence.
Dose and exposure intersect directly with PD credibility. The pivotal program relies on 400 mg BID fed. If PD depth at that exposure is slightly attenuated relative to 600 mg fasted, early ctDNA reductions may not translate into long-term resistance suppression. Sustained PD requires both adequate exposure and maintained dose intensity over time.
Combination biology muddies attribution. In the 2L setting, endocrine therapy continues to modulate ER signaling while PI3Kα inhibition dampens survival pathways. If benefit appears modest, it becomes unclear whether PD depth is insufficient or whether the pathway has a structural ceiling in CDK4/6-experienced tumors. The mechanistic limitation may be biological, not pharmacologic.
Scale is where PD narratives break. Variability in ctDNA clearance durability, discordance between radiographic response and molecular suppression, or inconsistent subgroup hazard ratios would suggest heterogeneous downstream control rather than uniform pathway dominance.
Overall, the catalyst will not re-litigate whether PI3Kα can be inhibited. The PD question is whether selective PI3Kα suppression materially delays resistance evolution in real tumors. Confidence upgrades only if ctDNA suppression translates into durable PFS separation at the pivotal dose, with stable hazard ratios over time and coherent benefit across mutation subtypes, signaling sustained pathway control rather than transient molecular pressure.
Clinical Trial Design
ReDiscover-2 is sensible but not “low-risk,” because it is an active-controlled, global Phase 3 that must prove durable superiority over an approved competitor while simultaneously defending a restrictive biomarker and metabolic selection strategy. The same choices that de-risk execution (tight eligibility, hierarchical endpoints, enriched biology) also create obvious attack surfaces if the topline is anything short of clearly practice-shifting.
Two interpretability layers, two different failure modes. First is the statistical outcome (does PFS separate cleanly against capivasertib); second is the narrative outcome (is the separation durable, clinically meaningful, and stable across the mutation subsets and baseline risk groups that matter). A technically positive result can still read as “not differentiated enough” if the absolute delta is modest, the kinase story does not generalize, or tolerability constraints narrow the real-world population.
Active comparator raises the bar and increases variance. This is not placebo-controlled on top of fulvestrant. Capivasertib + fulvestrant is an approved standard with known activity in this setting, so the trial is inherently higher-consequence: zovegalisib must win head-to-head, not just beat historical medians. If the control arm performs better than expected, the trial can still be “good drug, bad trial” from an investor perspective.
Hierarchical PFS endpoints are strategically smart and analytically risky. Prioritizing PFS in kinase mutations first can increase the probability of a win where biology is strongest, but it also advertises the vulnerability: if the kinase endpoint hits and the overall population is weaker, critics will argue the drug is effectively a kinase-domain niche rather than a broadly useful PI3Kα inhibitor. Conversely, if the kinase endpoint is noisy due to smaller effective N or imbalance, the entire hierarchy can become fragile even if the overall curve looks directionally favorable.
Eligibility enriches biology but narrows generalizability. Excluding known PTEN or AKT mutations is coherent mechanistically, but it forces a clean-genome narrative that may not translate to real practice where co-alterations are common and testing is imperfect. Metabolic gating (HbA1c <7%, fasting glucose <140 mg/dL) reduces predictable PI3K toxicity events, but it also means the registrational dataset may be unusually “metabolically healthy” relative to the real-world PIK3CA-mut population. That can inflate tolerability confidence and complicate uptake if clinicians perceive the label as metabolically conditional.
Dose-bridging is embedded in the design risk. The pivotal dose is 400 mg BID fed, while the promotional efficacy anchor comes from a different regimen. Even if PK supports exposure comparability, the only thing that matters here is clinical durability at the fed dose. If the experimental arm underdelivers, skeptics will argue the trial tested a more tolerable but less potent regimen, validating the “selectivity trades potency” concern.
Operational variance is a hidden risk in global PFS-driven trials. Multi-region enrollment introduces heterogeneity in scan timing, investigator behavior, supportive care, and subsequent therapy patterns. If curves converge late, if censoring differs by region, or if effect sizes vary materially by geography, the readout becomes easier to dismiss as operationally fragile even if statistically positive.
Narrative risk is amplified by endpoint optics. PFS as primary endpoint is standard, but “practice change” has to be earned. A significant hazard ratio can still feel incremental if the absolute median delta is small, if the tail does not separate, or if QoL and discontinuations undercut chronic use. OS is secondary, so the market will judge whether the PFS win is strong enough to carry commercial positioning without OS maturity.
Key questions this design needs to deliver
Does the experimental arm beat capivasertib in a way that feels clearly additive and durable, not just statistically positive?
Does the benefit hold across kinase and non-kinase PIK3CA mutations without the overall population collapsing into a subset story?
Does tolerability support maintained dose intensity over time, with discontinuations and metabolic management that do not erode real-world exposure?
Is the result robust across geographies and baseline risk strata, or does heterogeneity create an easy “where the signal was made” critique?
It’s not reckless, but it is high-consequence and moderately aggressive: head-to-head versus an approved competitor, hierarchical endpoint dependence, and restrictive molecular and metabolic selection mean a borderline win will be attacked hard. The design needs to deliver a clean, durable, broadly defensible PFS story at the pivotal dose, or the market will reframe success as narrow, fragile, or execution-dependent.
Competition Check
Baseline SoC sets a magnitude and durability bar, not a statistical bar.
In 2L HR+/HER2- PIK3CA-mut metastatic breast cancer, the relevant comparator for this catalyst is capivasertib + fulvestrant. That regimen has already demonstrated median PFS in the ~5–7 month range in CDK4/6-experienced patients. The competitive bar into ASCO June 2026 is therefore defined by clear and durable separation above that range at the pivotal 400 mg BID fed dose, not by modest hazard ratio wins versus historical controls.
Capivasertib is the real benchmark into the catalyst.
ReDiscover-2 is head-to-head against capivasertib, but ASCO serves as the read-through test of whether zovegalisib can convincingly outperform the downstream AKT approach. The bar is not whether PI3K pathway inhibition “works,” that is established, but whether mutant-selective PI3Kα inhibition translates into meaningfully longer PFS without converging toxicity. If the fed-dose dataset compresses toward historical 6–7 month medians or curves converge late, the differentiation narrative narrows quickly.
The catalyst test is structural differentiation, not statistical superiority alone.
Late-line oncology trials can be technically positive yet commercially muted. What the market will focus on is absolute median PFS, durability of curve separation, and consistency across mutation subsets, not just p-values. If the benefit feels incremental over capivasertib, enthusiasm for premium positioning compresses. If separation is clear and sustained, it resets expectations for best-in-class PI3Kα targeting.
Mutation subtype performance defines competitive positioning.
If benefit concentrates in kinase-domain mutations while non-kinase curves flatten, the opportunity looks narrower and easier for competitors to segment. Broad consistency across kinase and non-kinase PIK3CA mutations signals deeper pathway control and expands competitive ceiling. Subset-dependent benefit caps enthusiasm and complicates labeling narrative.
Other pathway inhibitors remain competitive context.
AKT and PI3K pathway agents have already established activity, and tolerability has historically constrained uptake. Any signal that suggests a mechanistic ceiling in CDK4/6-experienced disease compresses the valuation envelope for the class. Conversely, a clear durability advantage with cleaner metabolic management re-expands the multiple for selective PI3Kα targeting.
Regulatory and commercial credibility are the true moats.
Even with a statistically positive PFS outcome, safety, dose intensity, and durability will shape uptake. If hyperglycemia management, dose reductions, or discontinuations erode real-world exposure, the incremental benefit becomes harder to justify in a population already conditioned to pathway inhibitor tradeoffs.
Net: This catalyst is not about whether PI3Kα can be inhibited. It is about whether mutant-selective inhibition meaningfully extends disease control beyond an approved active comparator at the pivotal dose. A clean, durable separation expands the competitive ceiling. A marginal win or subset-fragile result reinforces the view that pathway inhibition in this setting has a structural efficacy ceiling.
Probability of Success Model
Strong Validation: best-in-class PI3Kα positioning de-risked
Thresholds:
ASCO June 2026 demonstrates clear and durable mPFS separation at 400 mg BID fed, holding in the ≥9–10 month range and meaningfully above the historical 5–7 month benchmark for CDK4/6-experienced disease. Hazard ratio remains stable over time without late curve convergence. Benefit is consistent across kinase and non-kinase PIK3CA mutations, dose intensity remains intact, and hyperglycemia or metabolic toxicity does not erode exposure. The dataset feels head-and-shoulders above capivasertib rather than statistically convenient, reinforcing that mutant-selective PI3Kα inhibition materially extends disease control.
Projected move (re-anchored to options): +45% to +70% clear best-in-class re-rate + Phase 3 de-risking)
Modest Validation: statistical win, differentiation debated
Thresholds:
mPFS is directionally strong but lands closer to 8–9 months, hazard ratio is favorable but not dominant, or curves show some late convergence. Benefit may skew toward kinase mutations with weaker non-kinase performance. Safety is manageable but introduces modest dose reductions or metabolic management complexity. The readout confirms activity at the pivotal dose, but stops short of redefining the competitive landscape versus capivasertib.
Projected move (re-anchored to options): +25% to +40% (short squeeze + partial re-rate, followed by digestion)
Equivocal / Mixed: biology confirmed, ceiling questioned
Thresholds:
Topline suggests activity at 400 mg fed but mPFS compresses toward 7–8 months, absolute delta versus historical comparators feels incremental, or subgroup dependence is obvious. Curves separate early but narrow over time. Dose intensity drift or rising discontinuations complicate interpretation. The narrative becomes “another PI3K pathway option,” and confidence in clear superiority entering Phase 3 weakens.
Projected move (re-anchored to options): −30% to −45% (volatility unwind, differentiation premium compresses)
Negative: pivotal-dose efficacy fails to clear the bar
Thresholds:
mPFS at 400 mg fed falls into the historical 5–7 month band, hazard ratio is modest or unstable, or curve separation lacks durability. Evidence of safety creep, increased metabolic events, or subset fragility amplifies disappointment. Interpretation shifts to “Phase 2 inflation at 600 mg fasted,” and the mutant-selective thesis loses structural credibility heading into ReDiscover-2.
Projected move (re-anchored to options): −45% to −70% (Phase 3 de-risking premium erased, valuation resets toward cash + early pipeline)
This catalyst is not about whether PI3Kα can be inhibited. It is about whether mutant-selective inhibition at the pivotal dose can materially extend disease control beyond an approved active comparator and historical pathway ceilings. The magnitude and durability of separation determine whether the best-in-class narrative expands or compresses.
Methodology & Base Assumptions
Program prior (blend of four base rates)
Modality. Mutant-selective PI3Kα inhibitor layered onto fulvestrant in 2L HR+/HER2- PIK3CA-mut metastatic breast cancer, with ASCO June 2026 serving as pivotal-dose validation ahead of head-to-head Phase 3 versus capivasertib. Credit: biologically validated PI3K pathway, precedent for PFS-driven approvals in CDK4/6-experienced disease, FDA alignment on 400 mg BID fed as registrational dose. Penalty: historical efficacy ceiling for pathway agents (~5–7 months mPFS), dose-bridging risk from 600 mg fasted to 400 mg fed, and active-comparator head-to-head exposure in Phase 3.
Biology. Mutant-selective PI3Kα inhibition intended to deliver deeper pathway suppression with reduced wild-type metabolic toxicity. Credit: PIK3CA is a validated oncogenic driver; early ctDNA clearance and tumor reduction demonstrate target engagement. Penalty: pathway redundancy (AKT/mTOR escape), subset dependence (kinase vs non-kinase mutations), and risk that selectivity trades potency for durability in heterogeneous tumors.
Indication. 2L HR+/HER2- PIK3CA-mut metastatic breast cancer post-CDK4/6 exposure. Credit: defined biomarker population, regulatory precedent for PFS primary endpoint, clear treatment sequencing. Penalty: resistance-evolved biology, competing approved pathway inhibitor (capivasertib), and relatively modest historical deltas in this setting.
Sponsor execution & ops. Global randomized Phase 3 (ReDiscover-2) with hierarchical PFS endpoints (kinase first, then overall) and active comparator. Credit: event-driven design, molecular stratification, regulatory familiarity with backbone. Penalty: subset fragility within hierarchical structure, metabolic gating limiting generalizability, regional heterogeneity, and interpretability risk if curves converge late.
Blended prior. Pre-ASCO program-level PoS that mutant-selective PI3Kα inhibition meaningfully exceeds the historical pathway ceiling at the pivotal dose: ~35–40%, reflecting validated biology but real incremental and dose-bridging risk.
How we update (Bayesian evidence stacking; conservative LRs)
PFS magnitude & durability (core driver).
mPFS ≥9–10 months at 400 mg fed with stable separation → LR ~1.3–1.6
mPFS 7–8 months or late convergence → LR ~0.6–0.9
Mutation subtype coherence (kinase stress test).
Consistent benefit across kinase and non-kinase → LR ~1.1–1.3
Kinase-dominant or heterogeneous signal → LR ~0.7–0.9
Dose intensity & metabolic sustainability.
Low Grade 3 hyperglycemia; minimal exposure erosion → LR ~1.1–1.3
Rising dose reductions or metabolic creep → LR ~0.6–0.8
Competitive differentiation optics.
Clear separation above capivasertib historical band → LR ~1.1–1.3
Incremental over AKT inhibition range → LR ~0.7–0.9
Posterior
Upside case (best-in-class positioning de-risked):
0.38 × 1.5 × 1.2 × 1.2 × 1.2 ≈ 0.65
(Requires ≥9–10 month mPFS, broad mutation consistency, and clean metabolic profile.)
Middle case (active but ceiling debated):
0.37 × 1.2 × 1.0 × 1.0 × 1.0 ≈ 0.44
(Statistically strong; differentiation still debated.)
Downside-lean (pathway ceiling persists):
0.36 × 0.8 × 0.8 × 0.8 × 0.8 ≈ 0.15–0.20
(mPFS compression, subset fragility, or exposure erosion compress narrative.)
Tier calibration
Strong Validation. Durable ≥9–10 month mPFS at 400 mg BID fed with broad kinase and non-kinase consistency, stable hazard ratio over time, and clean metabolic profile supporting full-dose exposure. Clear separation above the historical 5–7 month band and credible superiority optics versus capivasertib.
Projected move: +45–70%; best-in-class re-rate + Phase 3 de-risking premium expands. p₁ → ~60–65%.
Modest Validation. mPFS in the 8–9 month range with favorable but not dominant hazard ratio, some late curve convergence or kinase-skewed benefit, and manageable but visible safety tradeoffs. Activity confirmed at pivotal dose, differentiation debated.
Projected move: +25–40%; short squeeze + partial re-rate, followed by digestion. p₁ → ~40–50%.
Equivocal / Mixed. mPFS compresses toward 7–8 months, absolute delta feels incremental, subset dependence is obvious, or dose-intensity drift complicates durability. Early separation with narrowing curves over time.
Projected move: −30–45%; volatility unwind, differentiation premium compresses. p₁ → ~20–30%.
Negative. mPFS at 400 mg fed falls into the 5–7 month historical band, hazard ratio modest or unstable, durability lacking, or safety creep undermines exposure. “Phase 2 inflation” narrative dominates heading into ReDiscover-2.
Projected move: −45–70%; Phase 3 de-risking premium erased, valuation resets toward cash + early pipeline. p₁ → ≤20%.
Downside tail shifters
mPFS compression at 400 mg fed
Late curve convergence
Kinase-only benefit
Metabolic toxicity limiting dose intensity
Control arm outperformance narrowing absolute delta
What the model penalizes
Incrementalism in a saturated pathway. The model heavily taxes small absolute deltas, subset fragility, and dose-bridging uncertainty because CDK4/6-experienced PI3K pathway biology has repeatedly demonstrated a structural efficacy ceiling. A marginal win does not justify a best-in-class premium.
Bottom line: Pre-ASCO PoS sits in the mid-30s. It scales meaningfully higher only if the pivotal fed dose reproduces or approximates the original 10.3-month signal with durable, mutation-consistent separation. Anything short shifts probability mass left, consistent with the asymmetric downside embedded in single-asset, event-driven oncology setups.
Technical Considerations (Cash Runway and Short Interest)
Cash Runway
Relay ended 4Q 2025 with approximately $555M in cash and has guided runway into 2029 . Burn will remain elevated as ReDiscover-2 enrollment progresses, vascular anomalies expands, and preclinical NRAS advances, but there is no near-term balance sheet pressure into the ASCO June 2026 catalyst.
The price action implication into the catalyst is important: Relay is not entering ASCO with a forced-financing narrative. That means the stock should trade primarily as a clean adjudication of whether the 400 mg BID fed dose validates the earlier efficacy signal. If ASCO meaningfully de-risks best-in-class positioning, upside should not be capped by imminent dilution risk.
If the readout is mixed or compresses confidence in the pivotal dose, the cash runway provides operational insulation. However, runway does not protect valuation if the perceived differentiation versus capivasertib narrows. In that scenario, the stock can reset toward cash plus pipeline optionality rather than trade on solvency concerns.
Bottom line: runway reduces financing reflex volatility into ASCO, but it does not buffer against a mechanistic or competitive disappointment.
Short Interest
Short interest in Relay Therapeutics is elevated heading into the ASCO catalyst, signaling meaningful skepticism but not systemic positioning stress. As of the January 30, 2026 settlement, approximately 24.03 million shares were sold short, representing about 14.5% of the public float. The days-to-cover ratio is ~9.5 days based on average daily volume (~2.33 million shares), indicating persistent bearish interest but not extreme crowding.
This level of short interest reflects deliberate skepticism around pivotal-dose bridging risk, competitive pathway context, and the durability question at the 400 mg BID fed exposure. The implication into the catalyst is that upside on a clean ASCO validation should be driven primarily by fundamental rerating rather than mechanical squeeze dynamics. A clear, durable mPFS separation could trigger some covering given the ~9.5-day cover horizon, but any squeeze is likely an accelerant rather than the core driver of the move.
On the downside, elevated but manageable short positioning means disappointment can be absorbed without a forced unwind. If the dataset compresses toward historical PI3K pathway ceilings or shows subset dependency, existing shorts are unlikely to face structural pressure, and incremental short positioning could build as narrative risk transitions to Phase 3 uncertainty.
Bottom line: positioning reflects deliberate skepticism rather than instability. The stock is set up to move on whether ASCO meaningfully expands or compresses confidence in mutant-selective PI3Kα durability at the pivotal dose, not on technical fragility or forced positioning dynamics.
WHAT THIS MEANS FOR YOU
Looking at the analysts results and price coverage, those who cover the company rate as a STRONG BUY with 4/4 buy ratings. Keep in mind analyst ratings ALWAYS must be taken with a grain of salt as bearish analysts do not have long careers for obvious reasons.
The stock is currently trading at $10. The lowest analyst estimate has this one trading at $13. The upside scenario is at $17 - ~.75x+ upside with downside potential over the longer timeframe.
If we look at options pricing, and specifically IMPLIED VOLATILITY we can get a sense of the size of the move the traders are projecting. IF you do the math you get about a ~+65% move to the upside, and a -70% move to the downside. That would put the options projected price projections at ~$16.50 to the upside and ~$3 to the downside. Again, this is for a play on the short term catalyst which is a different timeframe from the 1yr analyst targets shown above.
Hedge funds have been buying into the catalyst.
HF positions increasing.
WHAT THEY ARE SAYING ON SOCIALS
Small Cap Strategist notes bullish trading signals
Top Stock Alerts syas big move developing
Michael Smith notes better-than-expected financial results
CONCLUSION
RLAY’s setup into ASCO June 2026 is ultimately simpler than the broader PI3K pathway debate. The catalyst does not need to re-prove that PI3Kα inhibition works; it needs to demonstrate that mutant-selective PI3Kα suppression at 400 mg BID fed can meaningfully extend 2L PFS beyond the historical 5–7 month ceiling and establish clear differentiation versus capivasertib.
That requires a clean, end-to-end chain: statistically persuasive mPFS separation at the pivotal dose, durable curve behavior without late convergence, consistent benefit across kinase and non-kinase PIK3CA mutations, and metabolic safety that preserves full-dose exposure over time. The market will care far less about nominal statistical significance than about absolute median PFS, hazard ratio stability, tail durability, and whether dose intensity holds.
For RLAY, success means ASCO clearly validating that the 400 mg fed regimen reproduces or approximates the original 10.3-month signal and positions zovegalisib as best-in-class within the PI3K pathway. A durable and clinically meaningful dataset would strengthen confidence entering ReDiscover-2 and mechanically lift program-level PoS assumptions.
If the update is mixed, statistically positive but compressed toward 7–8 months, with early separation and later curve convergence or mutation-dependent benefit, investors are likely to fade the differentiation narrative. In CDK4/6-experienced oncology, magnitude and durability matter more than technical success. A marginal win reinforces the view that PI3K pathway inhibition in this setting has a structural ceiling.
The best near-term outcome for RLAY is a practice-relevant ASCO dataset: ≥9–10 month durability at 400 mg fed, broad mutation consistency, and clean metabolic tolerability that supports sustained exposure. That would expand the perceived pathway ceiling and support premium positioning ahead of Phase 3.
Anything short of that keeps selective PI3Kα inhibition in the “incremental in a saturated pathway” bucket, with valuation anchored closer to cash plus early pipeline optionality rather than clear best-in-class differentiation.
Options are correctly pricing wide tails into the event, reflecting that this catalyst resolves the pivotal-dose durability question for the program, not whether PI3K biology is real.
Options are pricing wide tails into the 2026 window showing +60% / - 70% potential.
June 18, 2026 weekly expiration is clearly being used as the event wrapper for ASCO, and the structure is more nuanced than simple “upside vs downside” hedging.
Calls: positioning is concentrated but not aggressively skewed. The heaviest open interest sits at $12C (95 OI) and $14C (63 OI), with smaller but present interest at $11C (16 OI), $13C (18 OI), and $10C (14 OI). Notably, the $10 strike saw very large same-day volume (745 contracts) versus modest OI (27), suggesting fresh positioning rather than legacy overhang. That flow likely represents short-dated event speculation rather than structural long-term conviction.
There is no visible wall at $18–$20 or extreme OTM lottery clustering. The upside positioning is laddered through $10–$14, implying traders are underwriting a reversion into the low-to-mid teens rather than pricing a blowout move back to prior cycle highs. This looks like controlled upside optionality, not squeeze-driven convexity.
Puts: relatively sparse and shallow. Open interest at $6P (9 OI), $7P (1 OI), and $8P (3 OI) is minimal. There is no dense downside cluster comparable to the call side. That suggests traders are not aggressively hedging a collapse scenario into the event. Skew appears call-biased relative to put depth at this expiry.
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
We are now publishing 7x per week according to the following cadence:
Mondays: Stock Analysis & Biotech Catalysts
Tuesdays: Biotech hot topics (X-article)
Wednesdays: Podcast
Thursdays: Public & Private Biotech Markets
Fridays: Your Weekly Biotech Fix
Saturdays: Podcast
Sundays: Biotech Strategic Topics
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS